Business Context and Reporting Period
Company: Aptevo Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2022
Principal Executive Offices: Seattle, Washington
This filing reports the entry into a material definitive agreement regarding the company's Rights Agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance agreement and does not contain financial performance data.
Material Changes
On November 4, 2022, the Company entered into Amendment No. 2 to its Rights Agreement with Broadridge Corporate Issuer Solutions, Inc. The primary material change is the extension of the "Final Expiration Date" for the contingent rights to purchase Series A Junior Participating Preferred Stock to November 4, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the full text of Amendment No. 2 by reference as Exhibit 4.1. No specific outlook or guidance regarding future operations or financial performance is provided in this document.
Risks and Contingencies: The filing notes that the description of the Amendment is qualified in its entirety by reference to the complete text of the attached exhibit.
Investor Verification Checklist
- Verify the full terms of Amendment No. 2 by reviewing Exhibit 4.1 attached to the filing.
- Confirm the new Final Expiration Date of November 4, 2023, for the Rights Agreement.
- Review the definition of "Final Expiration Date" and related language modifications within the Rights Agreement.
- Check subsequent filings for any financial updates, as this 8-K contains no financial metrics.